Dermatomyositis and Polymyositis Studies - The Myositis Association

The following list of published research is intended to serve as a resource for study of inflammatory myopathies.

2021

Rohit Aggarwal, MDa, Christina Charles-Schoeman, MDb, Joachim Schessl, MDc, Mazen M. Dimachkie, MDd, Irene Beckmanne, Todd Levine, MDf. ProDERM-Study-Protocolphase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”). Aggarwal et al. Medicine (2021) 100:1.

2020

Parks CG, Wilkerson J, Rose KM, Faiq A, Farhadi PN, Long CS, MS, Bayat N, Brunner HI, Goldberg B, JA McGrath, Miller FW, and Rider LG. Association of Ultraviolet Radiation Exposure with Dermatomyositis in a National Myositis Patient Registry MYOVISION. Arthritis Care Res (Hoboken). 2020 Nov; 72(11): 1636–1644. doi: 10.1002/acr.24059.

2019

Christopher-Stine L, Kelly W, Wan G, Kobert L, Reed M. Polymyositis (PM) and Dermatomyositis (DM) symptom flares and associated impact from the patient perspective [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

2018

Labrador-Horrillo M and Selva-O’Callaghan A. Cancer-associated Dermatomyositis: Does the PD-1 checkpoint pathway play a role? J Rheumatol 2018. 45(6);731-732.
Victoria P. Werth, David Pearson, Joyce Okawa, Rui Feng, Josef Concha, Basil Patel, Emily Hejazi, Caitlin Cornwall, Scott Constantine, Barbara White. Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001. ACR/ARHP Annual Meeting, October 23, 2018.
Nithin Reddy, Majid Zeidi, Barbara White, Victoria P. Werth. Lenabasum, a cannabinoid type 2 receptor agonist, reduces T-cell population and downregulates type 1 and 2 interferon activities in lesional dermatomyositis skin. ACR/ARHP Annual Meeting, October 24, 2018.
Ayodeji Adegunsoye, Justin M. Oldham, Shashi K. Bellam, Jonathan H. Chung, Paul A. Chung, Kathleen M. Biblowitz, Steven Montner, Cathryn Lee, Scully Hsu, Aliya N. Husain, Rekha Vij, Gokhan Mutlu, Imre Noth, Matthew M. Churpek, Mary E. Strek. African-American race and mortality in interstitial lung disease: A multicentre propensity-matched analysis. Eur Respir J. 2018 June; 51(6). doi:10.1183/13993003.00255-2018.

2017

Edison K, Brod B. Burden of skin disease report: Implications for dermatology. J Am Acad Dermatol. 2017.
Buckley, Lenore, Gordon Guyatt, Howard A. Fink, et al. American College of Rheumatology guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis & Rheumatology. 2017, 69(8): 2326-5205. doi. 10.1002/art.40137.
Noemí De Luna, Xavier Suárez-Calvet, Cinta Lleixà, Jordi Diaz-Manera, Montse Olivé, Isabel Illa, Eduard Gallardo. Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis. Scientific Reports. 2017, 7:8595. DOI 10.1038/s41598-017-09309-8.
Xavier Suárez-Calvet, Eduard Gallardo, Iago Pinal-Fernandez, Noemi De Luna, Cinta Lleixà, Jordi Díaz-Manera, Ricardo Rojas-García, Ivan Castellví, M. Angeles Martínez, Josep M. Grau, Albert Selva-O’Callaghan, Isabel Illa. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Research & Therapy. 2017, 19:174. DOI 10.1186/s13075-017-1383-0.
Victoria P. Werth, Emily Hejazi, Sandra M. Pena, Jessica S. Haber, Joyce Okawa, Rui Feng, Kirubel Gabre, Josef Concha, Caitlin Cornwall, Nancy Dgetluck, Scott Constantine, Barbara White. A phase 2 study of safety and efficacy of anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. Abstract presented at ACR/ARHP Annual Meeting, November 7, 2017.
Morrell TJ, Mortensen WS, Langley S. Amyopathic dermatomyositis with plantar keratoderma responding to methotrexate therapy. Cutis. 2017. 100(2); E20-E24.
Iago Pinal-Fernandez, Maria Casal-Dominguez, Julio A. Huapaya, Jemima Albayda, Julie J. Paik, Cheilonda Johnson, Leann Silhan, Lisa Christopher-Stine, Andrew L. Mammen, Sonye K. Danoff. A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology 2017;56:999-1007. doi:10.1093/rheumatology/kex02.
[TMA-funded research]
Michael C. Kwa, Kaveh Ardalan, Anne E. Laumann, Jonathan I. Silverberg. Predictors of hospitalization, length of stay, and cost of care among adults with dermatomyositis in the United States. Arthritis Care & Research. 2017; 69(9): 1391–1399. DOI 10.1002/acr.23190.

2016

Andrew L. Mammen, MD, PhD,corresponding author Livia Casciola-Rosen, PhD, Lisa Christopher-Stine, MD, MPH, Thomas E. Lloyd, MD, PhD, and Kathryn R. Wagner, MD, PhD. Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology, Neuroimmunology & Neuroinflammation. 2015 Dec; 2(6): e172. Published online 2015 Nov 19. doi: 0.1212/NXI.0000000000000172.
Lorenzo Cavagna, MD, Laura Nuño, MD, Carlo Alberto Scirè, MD, Marcello Govoni, MD, Francisco Javier Lopez Longo, MD, Franco Franceschini, MD, Rossella Neri, MD, Santos Castañeda, MD, Walter Alberto Sifuentes Giraldo, MD, Roberto Caporali, MD, Florenzo Iannone, MD, Enrico Fusaro, MD, Giuseppe Paolazzi, MD, Raffaele Pellerito, MD, Andreas Schwarting, MD, Lesley Ann Saketkoo, MD, Norberto Ortego-Centeno, MD, Luca Quartuccio, MD, Elena Bartoloni, MD, Christof Specker, MD, Trinitario Pina Murcia, MD, Renato La Corte, MD, Federica Furini, MD, Valentina Foschi, MD, Javier Bachiller Corral, MD, Paolo Airò, MD, Ilaria Cavazzana, MD, Julia Martínez-Barrio, MD, Michelle Hinojosa, MD, Margherita Giannini, MD, Simone Barsotti, MD, Julia Menke, MD, Kostantinos Triantafyllias, MD, Rosetta Vitetta, MD, Alessandra Russo, MD, Gianluigi Bajocchi, MD, Elena Bravi, MD, Giovanni Barausse, MD, Roberto Bortolotti, MD, Carlo Selmi, MD, Simone Parisi, MD, Carlomaurizio Montecucco, MD, and Miguel Angel González-Gay, MD, on Behalf of AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group. Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (Baltimore). 2015 Aug; 94(32): e1144. Published online 2015 Aug 14. doi: 10.1097/MD.0000000000001144.
E.S. Robinson, R. Feng,J. Okawa,and V.P. Werth. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. NCBI Resources. Br J Dermatol. Author manuscript; available in PMC 2016 Jan 1. Published in final edited form as: Br J Dermatol. 2015 Jan; 172(1): 169–174. Published online 2014 Nov 30. doi: 10.1111/bjd.13167 PMCID: PMC4333145 NIHMSID: NIHMS603151.
Kari Oakes. Be alert for dermatomyositis without muscle disease. Family Practice News. 2016, Sept. 28.
Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, Ascherman DP, Levesque MC. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016 Jun; 55(6):991-9. doi: 10.1093/rheumatology/kev444. Epub 2016 Feb 16.
Allenbach Y, Leroux G, Suárez-Calvet X, Preusse C, Gallardo E, Hervier B, Rigolet A, Hie M, Pehl D, Limal N, Hufnagl P, Zerbe N, Meyer A, Aouizerate J, Uzunhan Y, Maisonobe T, Goebel H-H, Benveniste O, Stenzel W, and the French Myositis Network. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies. The American Journal of Pathology. 2016;186(3).
Y. Allenbach, G. Leroux, X. Suárez-Calvet, C. Preusse, E. Gallardo, B, Hervier, A, Rigolet, M. Hie, D. Pehl, N. Limal, P. Hufnagl, N. Zerbe, A. Meyer, J. Aouizerate, Y. Uzunhan, T. Maisonobe, H.H. Goebel, O. Benveniste, W. Stenzel, and the French Myositis Network. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies common interferon signature but distinct NOS2 expression. American Journal of Pathology, 2016, 186(3). DOI: 10.1016/j.ajpath.2015.11.010.
Shu X, Peng Q, Lu X, Wang G. HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis/dermatomyositis with interstitial lung disease. PLoS ONE. 2016, 11(8): e0161436. doi:10.1371/journal.pone.0161436
Ingela Loell, Joan Raouf, Yi-Wen Chen, Rongye Shi, Inger Nennesmo, Helene Alexanderson, Maryam Dastmalchi, Kanneboyina Nagaraju, Marina Korotkova, Ingrid E. Lundberg. Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents. Arthritis Research & Therapy. 2016, 18:136. DOI 10.1186/s13075-016-1033-y.

2015

Fowzia Ibrahim, Ernest Choy, Patrick Gordon, Caroline J. Doré, Alan Hakim, George Kitas, David Isenberg, Bridget Griffiths, Bryan Lecky, Kuntal Chakravarty, John Winer, Katalin Danko, Robert G. Cooper, Beverley White-Alao and David L. Scott. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. The British Society for Rheumatology Biologics Register. Rheumatology (2014) doi: 10.1093/rheumatology/keu442.
Thorsten Hornung, M.D., Viktor Janzen, M.D., Franz-Josef Heidgen, M.D., Dominik Wolf, M.D., Thomas Bieber, M.D., Ph.D. and Joerg Wenzel, M.D. Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. The New England Journal of Medicine. N Engl J Med 2014; 371:2537-2538December 25, 2014DOI: 10.1056/NEJMc1412997.
Lenka Pleštilová, Heřman Mann, Lucie Andrés Cerezo1, Ondřej Pecha, Jiří Vencovský and Ladislav Šenolt. The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Research & Therapy 2014, 16:468 doi:10.1186/s13075-014-0468-2.
Han Wang, Yingying Cai, Lin Cai, Yingchun Hu, Xianxiang Chen, Juelin Deng. Altered Lipid Levels in Untreated Patients with Early Polymyositis. PLOS ONE www.plosone.org 1 February 2014 | Volume 9 | Issue 2 |.
Tobias Ruck, Stefan Bittner, Tanja Kuhlmann, Heinz Wiendl, and Sven G. Meuth. Long-term efficacy of alemtuzumab in polymyositis. Rheumatology (Oxford). 2015 Mar; 54(3): 560–562. Published online 2014 Dec 30. doi: 10.1093/rheumatology/keu484.
Eleni Linos, David Fiorentino, Bharathi Lingala, Eswar Krishnan and Lorinda Chung. Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther. 2013; 15(1): R7. Published online 2013 Jan 8. doi: 10.1186/ar4135.
Takashi Kurita, Shinsuke Yasuda, Koji Oba, Toshio Odani, Michihito Kono, Kotaro Otomo, Yuichiro Fujieda, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (2015) 54 (1): 39-44. doi: 10.1093/rheumatology/keu166. First published online: April 24, 2014
Ann M. Reed, corresponding author Cynthia S. Crowson, Molly Hein, Consuelo Lopez de Padilla, Jeannette M. Olazagasti, Rohit Aggarwal, Dana P. Ascherman, Marc C. Levesque, Chester V. Oddis, and the RIM Study Group. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015; 16: 257. Published online 2015 Sep 17. doi: 10.1186/s12891-015-0710-3.
Samuel Katsuyuki Shinjoand Fernando Henrique Carlos de Souza. Update on the treatment of calcinosis in dermatomyositis. Scielo. Print version ISSN 0482-5004 Rev. Bras. Reumatol. vol.53 no.2 São Paulo Mar./Apr. 2013 http://dx.doi.org/10.1590/S0482-50042013000200009.

2014

Luciena Cegatto Martins Ortigosa and Vitor Manuel Silva dos Reis. A review of DM cases in Brazil. An Bras Dermatol. 2014 Sep-Oct; 89(5): 719–727. doi: 10.1590/abd1806-4841.20143422
Moises Labrador-Horrillo, Maria Angeles Martinez, Albert Selva-O’Callaghan, Ernesto Trallero-Araguas, Eva Balada, Miquel Vilardell-Tarresand and Cándido Juárez. Anti-MDA5 antibodies in dermatomyositis. J Immunol Res. 2014; 2014: 290797. Published online Feb 4, 2014. doi: 10.1155/2014/290797
Tu, Jenny; McLean-Tooke, Andrew; Junckerstorff, Reimar. Dermatomyositis with swelling. Dermatology Online Journal. http://escholarship.org/uc/item/1599r51x.
Alexandra Maria Giovanna Brunasso, Werner Aberer and Cesare Massone. New Onset of Dermatomyositis/Polymyositis during Anti-TNF-α Therapies: A Systematic Literature Review. ScientificWorldJournal. 2014; 2014: 179180. Published online Jan 29, 2014. doi: 10.1155/2014/179180
Melina Andrade Mattar, Bruno Gualano, Luiz Augusto Perandini, Samuel Katsuyuki Shinjo, Fernanda Rodrigues Lima, Ana Lúcia Sá-Pinto, and Hamilton Roschelcorresponding. Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis. Arthritis Res Ther. 2014; 16(5): 473. Published online Oct 25, 2014. doi: 10.1186/s13075-014-0473-5
Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, the RIM Study Group, Oddis CV. Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis & Rheumatology 2014;66:740–749. DOI 10.1002/art.38270.
C. Johnson, G.R. Connors, J. Oaks, S. Han, A. Truong, B. Richardson, N. Lechtzin, A.L. Mammen, L. Casciola-Rosen, L. Christopher-Stine, S.K. Danoff. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respiratory Medicine 2014; 108: 1542-1548. DOI: 10.1016/j.rmed.2014.09.003.

2013

Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. http://www.nbci.nlm.nih.gov/pubmed/21702020.
Chester V. Oddis, Ann M. Reed, Rohit Aggarwal, Lisa G. Rider, Dana P. Ascherman, Marc C. Levesque, Richard J. Barohn, Brian M. Feldman, Michael O. Harris-Love, Diane C. Koontz, Noreen Fertig, Stephanie S. Kelley, Sherrie L. Pryber, Frederick W. Miller, Howard E. Rockette, and the RIM Study Group. Rituzimab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis & Rheumatism. Vol. 65, No. 2, February 2013, pp 314-324 DOI 10.1002/art.37754
Angela Ceribelli, Micaela Fredi, Mara Taraborelli, Ilaria Cavazzana, Franco Franeschini, Marzia Quinzanini, Angela Tincani, Steven J Ross, Jason YF Chan, Brad Pauley, Edward KL Chan and Minoru Satoh. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Research and Therapy. Ceribelli et al. Arthritis Research & Therapy 2012, 14:R97. http://arthritis-research.com/content/14/2/R97.
Zhang Lu, MD; Wang Guo-chun, PhD; Ma Li, BS; Zu Ning, PhD. Cardiac Involvement in Adult Polymyositis or Dermatomyositis: A Systematic Review. Clinical Investigations.
Kei Kunimasa, Machiko Arita, Takashi Nakazawa, Maki Tanaka, Kazuya Tsubouchi, Satoshi Konishi, Yasushi Fukuda, Mika Saigusa, Hiroaki Nakagawa, Satoshi Ubukata, Yohei Korogi, Takao Fujii, Tsuneyo Mimori and Tadashi Ishida. The Clinical Characteristics of Two Anti-OJ (Anti-IsoleucyltRNA Synthetase) Autoantibody-Positive Interstitial Lung Disease Patients with Polymyositis/Dermatomyositis. Internal Medicine. DOI: 10.2169/internalmedicine.51.7425.
Nicole P Sandhu, Shaheen Zakaria, Amy C Degnim, Judy C Boughey. Dermatomyositis presenting as a paraneoplasic syndrome due to underlying breast cancer. BMJ Case Reports 2011;10.1136/bcr.10.2010.3416.
Fernando Henrique Carlos de SouzaI, Thiago Bitar Moraes BarrosII, Maurício Levy-NetoI II, Samuel Katsuyuki Shinjo IV. Adult dermatomyositis: experience of a Brazilian tertiary care center. Revista Brasileira de Reumatologia. Print version ISSN 0482-5004 Rev. Bras. Reumatol. vol.52 no.6 São Paulo Nov./Dec. 2012 http://dx.doi.org/10.1590/S0482-50042012000600008. Portuguese Version
Nicolas Prevel, Yves Allenbach, David Klatzmann, Benoit Salomon, and Olivier Benveniste. Beneficial role of rapamycin in experimental autoimmune myositis. PLoS One. 2013; 8(11): e74450. doi: 10.1371/journal.pone.0074450

2012

Todd Levine. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a restrospective case series . Drug Design, Development and Therapy 2012:6 133-139
Tahseen Mozaffar & Alan Pestronk. Myopathy with anti-Ko-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000; 68: 472-478.
Elena Schiopu, Kristine Phillips, Paul M MacDonald, Leslie Crofford and Emily Somers. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effects of corticosteriods, methotrexate and azathioprine. Arthrithis Research Ther. Published online 2012 January 21. doi: 10.1186/ar3704.

2011

Michael Benatar, MD. Dermatomyositis-Etanercept Trial. Journal Watch Neurology. October 4, 2011.
Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011 February ; 37(1): 100–109.

2010

E.C. Ebert. Gastrointestinal Ebert. Alimentary Pharmacology & Therapeutics 31, 359-365.
Andrew L. Mammen. Dermatomyositis and polymyositis Clinical presentation, autoantibodies, and pathogenesis. New York Academy of Sciences. Ann. N.Y. Acad. Sci. 1184 (2010) 134-153.
Andrew L. Mammen, Livia A. Casciola-Rosen, John C. Hall, Lisa Christopher-Stine, Andrea M. Corse, and Anthony Rosen. Expression of the Dermatomyositis Autoantigen Mi-2 in Regenerating Muscle. Arthritis & Rheumatism. Col. 60, No. 12, December 2009, pp 3784-3793. DOI 10.1002/art.24977.
Jennie T. Clarke and Victoria P. Werth. Rheumatic manifestations of skin disease. Current Opinion in Rheumatology. 2010, 22:78-84. DOI:10.1097/BOR.0b013e328333b9e2.

2009

Rider, Lachenbruch, Monroe, Ravelli, Cabalar, Feldman, Villalba, Myones, Pachman, Rennebohm, Reed and Miller for the IMACS Groups. Damage Extent and Predictors in Adult Juvenile Dermatomyositis and Polymyositis as determined with the myositis damage index. Arthritis & Rheumatism; vol. 60, No. 11, November 2009, pp 3425-3435. DOI 10.1002/art.24904.
Annaliese Tisseverasinghe, Sasha Bernatsky, Christian A. Pineau. Cardio PM/DM. The Journal of Rheumatology 2009: 36:9; doi: 10.3899/jrheum.090061.

2021

2020

2019

2018

2017

2016

2014

2013

2012

2011

2010

2009

2006 – 2007

2001 – 2005

1996 – 2000

1991 – 1995